<DOC>
	<DOCNO>NCT00003307</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Amifostine may protect normal cell side effect radiation therapy . PURPOSE : Phase II trial study effectiveness radiation therapy plus amifostine treating patient primary prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Amifostine Treating Patients With Primary Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine incidence , grade , time course acute grade 2 high gastrointestinal genitourinary toxicity patient primary prostate adenocarcinoma receive amifostine plus fractionated radiotherapy . II . Determine incidence nature toxicity associate amifostine patient . III . Assess tumor response treatment patient . IV . Assess impotency rate follow radiotherapy patient . OUTLINE : This open label study . Patients receive fractionate radiotherapy five day per week 7 week plus amifostine IV push 5 minute , 15 minute radiation treatment . Patients follow 1 month radiotherapy , every 3 month least 5 year . PROJECTED ACCRUAL : There 25 patient accrue study 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate adenocarcinoma Stage T1aT3b N0 M0 disease PSA least 10 ng/mL prior treatment Must risk seminal vesicle involvement 1025 % No palpable radiographic evidence seminal vesicle involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 24 month Hematopoietic : Not specify Hepatic : SGOT SGOT great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No severe cerebrovascular disease sustain hypotension secondary antihypotensive medication Other : No history inflammatory bowel disease No history malignancy nonmelanoma skin cancer No underlie medical psychiatric illness may impair ability participate study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy prostate area Surgery : No prior radical prostatectomy Other : No hypertensive medication blood pressure less 120/70</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>